{
    "clinical_study": {
        "@rank": "95956", 
        "arm_group": [
            {
                "arm_group_label": "100 mg GLPG1205 fasted", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 100 mg GLPG1205 as two capsules of 50 mg after an overnight fast"
            }, 
            {
                "arm_group_label": "100 mg GLPG1205 fed", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 100 mg GLPG1205 as two capsules of 50 mg exactly 30 minutes after the start of a high-fat, high-calorie breakfast"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the amount of compound present in the blood\n      (relative bioavailability) after a single oral administration of GLPG1205 given as a capsule\n      formulation in fasted versus fed conditions in male healthy subjects.\n\n      Also, the safety and tolerability of a single oral dose of GLPG1205 given as a capsule\n      formulation under fasted and fed conditions will be assessed."
        }, 
        "brief_title": "Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male, age 18-50 years\n\n          -  BMI between 18-30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Any condition that might interfere with the procedures or tests in this study\n\n          -  Drug or alcohol abuse\n\n          -  Smoking"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143856", 
            "org_study_id": "GLPG1205-CL-102", 
            "secondary_id": "2013-004771-12"
        }, 
        "intervention": {
            "arm_group_label": [
                "100 mg GLPG1205 fasted", 
                "100 mg GLPG1205 fed"
            ], 
            "description": "A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg", 
            "intervention_name": "100 mg GLPG1205", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerp", 
                    "country": "Belgium"
                }, 
                "name": "SGS LSS Clinical Pharmacology Unit Antwerp"
            }, 
            "investigator": {
                "last_name": "Wouter Haazen, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Two-way Cross-over Study to Determine the Oral Bioavailability of GLPG1205 After Single-dose Intake in Healthy Male Subjects as a Solid Formulation, With and Without Food", 
        "overall_contact": {
            "last_name": "Wouter Haazen, MD", 
            "phone": "+32 3 217 25 60"
        }, 
        "overall_official": {
            "affiliation": "Galapagos NV", 
            "last_name": "Fr\u00e9d\u00e9ric Vanhoutte, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To characterize and compare the amount of GLPG1205 in plasma ( relative bioavailability) in male healthy subjects after a single administration of a capsule formulation in a fasted versus fed condition.", 
            "measure": "The amount of GLPG1205 in plasma", 
            "safety_issue": "No", 
            "time_frame": "From predose up to 504 hours (Day 22) after study drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143856"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the safety and tolerability of a single dose of GLPG1205 administered as capsules fasted versus fed in male healthy subjects in terms of adverse events (AEs)", 
                "measure": "The number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 28 (+/-2) days after last study drug administration"
            }, 
            {
                "description": "To evaluate the safety and tolerability of a single dose of GLPG1205 administered as capsules fasted versus fed in male healthy subjects in terms of abnormal laboratory parameters", 
                "measure": "The number of subjects with abnormal laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 28 (+/-2) days after last study drug administration"
            }, 
            {
                "description": "To evaluate the safety and tolerability of a single dose of GLPG1205 administered as capsules fasted versus fed in male healthy subjects in terms of abnormal vital signs", 
                "measure": "The number of subjects with abnormal vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 28 (+/-2) days after last study drug administration"
            }, 
            {
                "description": "To evaluate the safety and tolerability of a single dose of GLPG1205 administered as capsules fasted versus fed in male healthy subjects in terms of abnormal electrocardiogram (ECG)", 
                "measure": "The number of subjects with abnormal electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 28 (+/-2) days after last study drug administration"
            }, 
            {
                "description": "To evaluate the safety and tolerability of a single dose of GLPG1205 administered as capsules fasted versus fed in male healthy subjects in terms of abnormal physical examination", 
                "measure": "The number of subjects with abnormal physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 28 (+/-2) days after last study drug administration"
            }
        ], 
        "source": "Galapagos NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galapagos NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}